Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | TPMT | P51580 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12191799 | 1.00 | KMT2A (0.49) | KMT2AMEN1PTPN1PDE4BCREBBP | |
| SCHEMBL2497731 | 0.90 | PTPN1 (0.42) | KMT2AMEN1PTPN1PDE4BCA12 | |
| SCHEMBL29377172 | 0.87 | PTPN1 (0.45) | KMT2APTPN1PDE4B | |
| SCHEMBL2060107 | 0.87 | PTPN1 (0.45) | KMT2APTPN1PDE4B | |
| SCHEMBL7802721 | 0.81 | PTPN1 (0.37) | PTPN1PDE4BCA1CA2 | |
| SCHEMBL1755976 | 0.80 | HSD11B1 (0.41) | KMT2AMEN1PTPN1PDE4B | |
| SCHEMBL12831493 | 0.79 | PTPN1 (0.39) | KMT2AMEN1PTPN1PDE4BCA12 | |
| SCHEMBL2780758 | 0.79 | L3MBTL1 (0.42) | PTPN1 | |
| SCHEMBL5166212 | 0.79 | PTPN1 (0.38) | KMT2AMEN1PTPN1PDE4B | |
| SCHEMBL225085 | 0.79 | KMT2A (0.65) | KMT2AMEN1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450522-B2 | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders | AMGEN INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8030354-B2 | 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes | AMGEN INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20100298367-A1 | Conformationally Constrained Carboxylic Acid Derivatives Useful for Treating Metabolic Disorders | AMGEN INC. | 2010-11-25 | — | — | US | disclosed |
| US-20090137561-A1 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137561-A1 | Substituted biphenyl GPR40 modulators | GPR119, GPR65, GPR55 | KMT2A 3040/4885MEN1 3240/4885PTPN1 1424/4885 |
| US-20100298367-A1 | Conformationally Constrained Carboxylic Acid Derivatives Useful for Treating Metabolic Disorders | PC, GOT2, CS | KMT2A 2883/4885MEN1 1233/4885PTPN1 4390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.